Payment overview · 2025
General Payments
$518.33
24 reported records · 7 companies
Healthcare provider profile · identity verified
David J Burrier, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWCOMERSTOWN, OH · NPI 1699769422
Verified facts
What the public records show
CMS Open Payments records show David J Burrier, MD received $518.33 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.05 | 31.1% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $102.01 | 19.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.60 | 18.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.15 | 12.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.13 | 8.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.29 | 7.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.10 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.33 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $144.75 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $102.01 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $98.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.40 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.15 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 133 |
| Omeprazole | Omeprazole | 445 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 82 |
| Lisinopril | Lisinopril | 339 | 100 |
| Losartan Potassium | Losartan Potassium | 310 | 83 |
| Gabapentin | Gabapentin | 272 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 272 | 44 |
| Metformin Hcl Er | Metformin Hcl | 264 | 61 |
| Eliquis | Apixaban | 251 | 47 |
| Furosemide | Furosemide | 203 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 52 |
| Sertraline Hcl | Sertraline Hcl | 186 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 38 |
| Potassium Chloride | Potassium Chloride | 171 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 37 |
| Prednisone | Prednisone | 134 | 70 |
| Famotidine | Famotidine | 126 | 23 |
| Donepezil Hcl | Donepezil Hcl | 123 | 14 |
| Tramadol Hcl | Tramadol Hcl | 123 | 25 |
| Carvedilol | Carvedilol | 116 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 24 |
| Memantine Hcl | Memantine Hcl | 109 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 101 | suppressed |
| Metformin Hcl | Metformin Hcl | 99 | 27 |
| Glimepiride | Glimepiride | 98 | 30 |
| Allopurinol | Allopurinol | 96 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 95 | 71 |
| Alprazolam | Alprazolam | 94 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 27 |
| Warfarin Sodium | Warfarin Sodium | 93 | 22 |
| Atenolol | Atenolol | 92 | 22 |
| Xarelto | Rivaroxaban | 90 | 17 |
| Trazodone Hcl | Trazodone Hcl | 88 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | suppressed |
| Ozempic | Semaglutide | 81 | suppressed |
| Simvastatin | Simvastatin | 73 | 18 |
| Mirtazapine | Mirtazapine | 70 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 69 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 16 |
| Jardiance | Empagliflozin | 67 | 20 |
| Baclofen | Baclofen | 66 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 21 |
| Spironolactone | Spironolactone | 65 | 15 |
| Olanzapine | Olanzapine | 64 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 12 |
| Buspirone Hcl | Buspirone Hcl | 58 | 19 |
| Farxiga | Dapagliflozin Propanediol | 57 | 12 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Risperidone | Risperidone | 54 | suppressed |
| Carbamazepine | Carbamazepine | 51 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 17 |
| Azithromycin | Azithromycin | 40 | 36 |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 11 |
| Cephalexin | Cephalexin | 32 | 26 |
| Finasteride | Finasteride | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Tradjenta | Linagliptin | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.33 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FARXIGA, Korlym, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error